Arbutus Biopharma (ABUS) vs Alumis (ALMS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Alumis (ALMS) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 50.1% versus a gain of 0.0%. Alumis is the larger company by market cap ($876.3 million vs $657.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | ALMS |
|---|---|---|
| Share price | $4.29 | $6.77 |
| Market cap | $657.55M | $876.28M |
| 1-day change | -4.24% | -2.31% |
| YTD return | -10.81% | -30.64% |
| 1-year return | 0.00% | +50.11% |
| 5-year return | +5.15% | — |
| P/E ratio (TTM) | 5.43 | — |
| EPS (TTM) | $0.79 | $-3.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $31.35 |
| 52-week low | $3.50 | $4.28 |
| Distance from 52-week high | -21.28% | -78.41% |
| Average volume | 4.65M | 2.44M |
| Shares outstanding | 153.28M | 129.44M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALMS has outperformed ABUS by 50.1 percentage points over the past year.
ABUS vs ALMS FAQ
Which is bigger, Arbutus Biopharma or Alumis?
Alumis (ALMS) is larger, with a market capitalization of $876.28M compared with $657.55M for Arbutus Biopharma (ABUS).
Which stock has performed better over the past year, ABUS or ALMS?
ALMS returned +50.11% over the past 12 months, compared with 0.00% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and Alumis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.